RECQL4 depletion led to increased sensitivity of the ovarian cancer cells to cisplatin and olaparib, a PARP inhibitor, which suggests that RECQL4 may be a critical component in the resistance of ovarian malignant cells to cisplatin. The gene discussed is RECQL4; the disease is ovarian carcinoma.